335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22649 | Non metastatic urothelial carcinoma candidate for surgery Cisplatin eligible and ineligible |
Thierry Gil | Ureters - bladder - urethra | Institut Jules Bordet | AURA | Trial closed for recruitment | Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers | thierry.gil@hubruxelles.be | 2 | 2 | |
| 22615 | after one line, biopsy | Philippe Aftimos | Breast | BIG | AURORA | Trial open for recruitment | BIG 14-01 AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer | philippe.aftimos@hubruxelles.be | 3 | 3 | |
| 22832 | 2 or 3 prior regimens, including one with VEGFR TKI | Nieves Martinez Chanza | Kidney cells carcinoma | Aveo Oncology | AV-951-15-303 | Trial closed | A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma | nieves.martinez-chanza@hubruxelles.be | 3 | 3 | |
| 29768 | Philippe Aftimos | Multiple | AstraZeneca | AZD 8205 | Trial open for recruitment | A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies | philippe.aftimos@hubruxelles.be | 1/2a | 1 | ||
| 29772 | Francesco Sclafani | Multiple | GSK | AZUR-2 219606 | Trial open for recruitment | A Phase 3, Double-Arm, Open-Label Study of Peri-operative Dostarlimab Monotherapy versus standard of care in Participants with Untreated Stage II/III dMMR/MSI-H | francesco.sclafani@hubruxelles.be | 3 | 3 | ||
| 22693 | HER+. Advanced or metastatic with PIK3CA mutation | Philippe Aftimos | Breast | Menarini | B PRECISE 01 | Trial closed | Open-label, multicentre, phase Ib dose escalation study of MEN1611, a PI3K inhibitor combined with trastuzumab +/- fulvestrant, in subjects with PIK3CA mutated HER2-positive locally recurrent unresectable (advanced) or metastatic (a/m) breast cancer progressed to anti-HER2 based therapy | philippe.aftimos@hubruxelles.be | 1/1b | 1 | |
| 22613 | Nodule 5-20 mm of undetermined nature in at least one lung. | Thierry Berghmans | Lung | European Lung Cancer Working Party | B079201215796 | Trial open for recruitment | Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party | 2 | 2 | ||
| 22621 | Lung cancer No prior treatment |
Anne-Pascale Meert | Lung | European Lung Cancer Working Party | B079201523324 | Trial closed for recruitment | Does inflammation have a significant implication in Lung Cancer evolution? | ap.meert@hubruxelles.be | |||
| 22967 | Relapsed or refractory precursor CD22-positive B-cell ALL and who are eligible for HSCT - Have 1 or more of the following risk factors for developing VOD: a. Due to receive Salvage 2 or greater; b. Prior HSCT;c. Age >=55 years |
Sebastian Wittnebel | Acute leukemia | Pfizer | B1931030 | Trial closed | A phase 4, open label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno occlusive disease | Sebastian.Wittnebel@hubruxelles.be | 4 | 4 | |
| 22671 | Biopsy | Philippe Aftimos | Multiple | Pfizer | B9991025 | Trial closed for recruitment | Phase 1b/2 study to evaluate safety and anti-tumor activity of Avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (PARP) inhibitor Talazoparib in patients with locally advanced or metastatic solid tumors | philippe.aftimos@hubruxelles.be | 2 | 2 | |
| 22696 | KRAS/RAS mutation | Nuria Kotecki | Multiple | Pfizer | B9991033 | Trial closed | A phase 1b/2 study to evaluate safety and clinical activity of Avelumab in combination with Binimetinib with or without Talazoparib in patients with locally advanced or metastatic ras-mutant solid tumors | Nuria.Kotecki@hubruxelles.be | 1/2 | 1 | |
| 22935 | Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial. | Géraldine Gebhart | Multiple | Bayer | BAY 88-8223 / 16996 | Trial closed for recruitment | A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride | geraldine.gebhart@hubruxelles.be | 4 | 4 | |
| 22619 | *HER negative hormone receptor positive breast cancer * received at least one line of hormonal therapy in the metastatic setting *eligible for exemestane and everolimus * experienced no more than 2 skeletal related event (SRE) |
Géraldine Gebhart | Breast | Bayer | BAY 88-8223 / 17096 | Trial closed for recruitment | A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with exemestane and everolimus versus placebo in combination with exemestane and everolimus when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects with bone metastases | geraldine.gebhart@hubruxelles.be | 2 | 2 | |
| 29415 | - Newly diagnosed patients with myelodysplastic syndromes defined by WHO 2016 criteria that are about to start treatment. - Patients with a known diagnosis of MDS, irrespective of IPSS and irrespective of time of diagnosis that are about to start a new th |
Sebastian Wittnebel | Blood | BE-QUALMS | Trial closed | A Multicenter observational Belgian study assessing the impact of newly started treatment on the QOL in patients suffering from myelodysplastic syndromes | Sebastian.Wittnebel@hubruxelles.be | 4 | 4 |